-
公开(公告)号：US20250072282A1
公开(公告)日：2025-02-27
申请号：US18724329
申请日：2022-12-29
Applicant: SFC CO., LTD.
Inventor： Jin-hwi CHO , Se-jin YU , So-young SHIM , Yong-woon YANG
IPC: H10K85/60 , C07C15/20 , C07C43/275 , C07C255/52 , C07D209/86 , C07D213/16 , C07D215/06 , C07D241/42 , C07D265/38 , C07D279/22 , C07D307/77 , C07D333/76 , C07D407/10 , C07D409/14 , C07F7/08 , C07F7/30 , C09K11/02 , C09K11/06 , H10K50/12
Abstract: The present invention relates to an anthracene derivative compound having a characteristic structure in which an aliphatic aromatic mixed ring group is substituted, and to an organic light-emitting device comprising same. The present invention relates to a high-efficiency and long-lifespan organic light-emitting device having remarkably improved luminous efficiency and lifespan characteristics by adopting the anthracene derivative compound according to the present invention as a host of a light-emitting layer, and adopting a polycyclic compound having a characteristic structure as a dopant of the light-emitting layer.
-
公开(公告)号：US20250066662A1
公开(公告)日：2025-02-27
申请号：US18768028
申请日：2024-07-10
Inventor： Zhiqian GUO , Juan LI , Yutao ZHANG , Yao LU , Chenxu YAN , Meiling ZHAO , Xiuyan ZHAO , Weihong ZHU
IPC: C09K11/06 , C07D309/34 , C07D407/10 , G01N21/64
Abstract: A luminescent probe and its preparation method and application are provided. The luminescent probe has a steric hindrance group R1 of aliphatic hydrocarbon structure such as adamantane or norborneol, a detection group R2 of nitrobenzyl and its derivative structure, an electron-withdrawing group R3 containing cyano group and an electron-donating group methoxy group. In the presence of HSA or BSA, the detection group is cut off to form a parent structure that exposes atomic oxygen anions and is activated under external light irradiation, the luminescent probe can be used in solution or cells, when detecting HSA or BSA, the luminescent probe has obvious chemiluminescence characteristics, which can sensitively distinguish HSA and BSA, quantitatively analyze HSA and BSA, and determine the mixing ratio of HSA and BSA at the same time, and the luminescent probe has been successfully used for cell fluorescence imaging.
-
公开(公告)号：US20250066378A1
公开(公告)日：2025-02-27
申请号：US18936608
申请日：2024-11-04
Applicant: Hoffmann-La Roche Inc.
Inventor： Valerie Runtz-Schmitt , Patrick Schnider , Cosimo Dolente , Bernhard Fasching
IPC: C07D491/107 , C07D491/10 , C07D491/12 , C07D491/20 , C07D498/10 , C07D519/00
Abstract: The present invention provides spiro-oxazolones, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The present compounds are useful as therapeutics acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.
-
公开(公告)号：US20250066376A1
公开(公告)日：2025-02-27
申请号：US18893561
申请日：2024-09-23
Applicant: Nirsum Laboratories, Inc.
Inventor： Nikej N. Shah
IPC: C07D489/08 , A61K31/485 , C07D221/28
Abstract: Provided herein are prodrugs of opioid receptor antagonists such as samidorphan, methocinnamox, and naloxone, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases and disorders such as a depressive disorder, alcohol dependence and opioid dependence.
-
公开(公告)号：US20250066369A1
公开(公告)日：2025-02-27
申请号：US18726919
申请日：2023-01-06
Applicant: NodThera Limited
Inventor： Mark G. BOCK , David HARRISON , Jane E. SCANLON
IPC: C07D487/04 , A61K31/5025 , A61K31/506 , C07D471/04 , C07D491/048 , C07D495/04 , C07D519/00
Abstract: The present disclosure relates to compounds of Formula (III): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.
-
Patent Agency Ranking
公开(公告)号：US20250066363A1
公开(公告)日：2025-02-27
申请号：US18813538
申请日：2024-08-23
Applicant: Incyte Corporation
Inventor： Joshua Hummel , Liana Hie , Jacob J. Lacharity , Xiaolei Li , Ding-Quan Qian , Xiaozhao Wang , Bo Wei
IPC: C07D473/18 , A61K31/496 , A61K31/522 , C07D471/04 , C07D487/04
Abstract: The present application provides bicyclic compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
-
7.发明申请公开(公告)号：US20250066359A1
公开(公告)日：2025-02-27
申请号：US18724366
申请日：2022-12-27
Inventor： Jianhua SHEN , Xin XIE , Yanglong ZHANG , Tingting ZHAO , Fanghui HAN , Ying YUN
IPC: C07D471/10 , A61K31/397 , A61K31/407 , A61K31/437 , A61K31/438 , A61K31/444 , A61K31/4523 , A61K31/495 , A61K31/496 , A61K31/5386 , A61K45/06 , A61P1/16 , A61P3/10 , C07D205/12 , C07D211/96 , C07D211/98 , C07D221/20 , C07D295/26 , C07D401/04 , C07D471/04 , C07D487/10 , C07D498/10
Abstract: Provided are a class of compounds which have a structure as shown in the following general formula (I) and are used as somatostatin receptor subtype 5 (SSTR5) antagonists, and a pharmaceutical composition and the use thereof. The compounds have good SSTR5 antagonistic activities, and can be used for preparing drugs for treating related diseases mediated by SSTR5.
-
公开(公告)号：US20250066358A1
公开(公告)日：2025-02-27
申请号：US18718012
申请日：2022-12-09
Applicant: Bala Therapeutics, Inc.
Inventor： Ruben Abagyan , Vladislav Zenonovich Parchinsky , Alexander Khvat , Alexandre Vasilievich Ivachtchenko , Nikolay Savchuk
IPC: C07D471/10 , A61K31/517 , A61K31/519 , A61K31/5377 , A61K31/538 , A61K31/5415 , A61K31/554 , C07D401/12 , C07D403/12 , C07D519/00
Abstract: The present invention is directed to the compounds of Formula (I)—inhibitors of the interaction of menin and MLL. The inhibitors described herein can be useful in the treatment of diseases or disorders associated with menin-MLL interaction, such as cancer. In particular, the invention is concerned with compounds and pharmaceutical compositions inhibiting/blocking menin-MLL interaction, methods of treating diseases or disorders associated with menin-MLL interaction, and methods of synthesizing these compounds.
-
公开(公告)号：US20250066356A1
公开(公告)日：2025-02-27
申请号：US18941521
申请日：2024-11-08
Applicant: INTERLINE THERAPEUTICS, INC.
Inventor： Robert J. MOREAU , David C. TULLY , Zuojun GUO , Mario G. CARDOZO , Zachary K. SWEENEY
IPC: C07D471/04 , A61K31/4745
Abstract: The present invention relates to imidazo[4,5-c]quinoline compounds of Formula (I), and pharmaceutically acceptable salts thereof. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, or inflammatory bowel disease such as Crohn's disease.
-
公开(公告)号：US20250066355A1
公开(公告)日：2025-02-27
申请号：US18935237
申请日：2024-11-01
Applicant: Celgene Quanticel Research, Inc.
Inventor： Amogh Boloor , Toufike Kanouni , Jeffrey Alan Stafford , James Marvin Veal , Michael Brennan Wallace
IPC: C07D471/04 , C07D487/04
Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
-
-
-
-
-
-
-
-
-
Search Results
325249
records
(took 0.12 seconds)
